Universal and hypoimmunogenic pluripotent stem cells for clinical usage
- PMID: 37678974
- DOI: 10.1016/bs.pmbts.2023.02.014
Universal and hypoimmunogenic pluripotent stem cells for clinical usage
Abstract
It is urgent to prepare and store large numbers of clinical trial grade human pluripotent stem (hPS) cells for off-the-shelf use in stem cell therapies. However, stem cell banks, which store off-the-shelf stem cells, need financial support and large amounts of technicians for daily cell maintenance. Therefore, it is valuable to create "universal" or "hypoimmunogenic" hPS cells with genome editing engineering by knocking in or out immune-related genes. Only a small number of universal or hypoimmunogenic hPS cell lines should be needed to store for off-the-shelf usage and reduce the large amounts of instruments, consumables and technicians. In this article, we consider how to create hypoimmunogenic or universal hPS cells as well as the demerits of the technology. β2-Microglobulin-knockout hPS cells did not harbor human leukocyte antigen (HLA)-expressing class I cells but led to the activation of natural killer cells. To escape the activities of macrophages and natural killer cells, homozygous hPS cells having a single allele of an HLA class I gene, such as HLA-C, were proposed. Major HLA class Ia molecules were knocked out, and CD47, HLA-G and PD-L1 were knocked in hPS cells utilizing CRISPR/Cas9 genome editing. Finally, some researchers are trying to generate universal hPS cells without genome editing. The cells evaded the activation of not only T cells but also macrophages and natural killer cells. These universal hPS cells have high potential for application in cell therapy.
Keywords: Cell therapy; Human leukocyte antigen; Hypoimmunogenic hPS cells; Immune privilege; Off-the-shelf cells; Universal hPS cells.
Copyright © 2023. Published by Elsevier Inc.
Similar articles
-
Generation of universal and hypoimmunogenic human pluripotent stem cells.Cell Prolif. 2020 Dec;53(12):e12946. doi: 10.1111/cpr.12946. Epub 2020 Nov 11. Cell Prolif. 2020. PMID: 33174655 Free PMC article. Review.
-
Transient characteristics of universal cells on human-induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources.Cell Prolif. 2021 Mar;54(3):e12995. doi: 10.1111/cpr.12995. Epub 2021 Feb 1. Cell Prolif. 2021. PMID: 33522648 Free PMC article.
-
Development of a baculoviral CRISPR/Cas9 vector system for beta-2-microglobulin knockout in human pluripotent stem cells.Mol Genet Genomics. 2024 Aug 1;299(1):74. doi: 10.1007/s00438-024-02167-w. Mol Genet Genomics. 2024. PMID: 39085666
-
Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.Stem Cell Res Ther. 2024 Jul 2;15(1):193. doi: 10.1186/s13287-024-03810-4. Stem Cell Res Ther. 2024. PMID: 38956724 Free PMC article.
-
Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy.J Immunol Res. 2014;2014:518135. doi: 10.1155/2014/518135. Epub 2014 Jul 9. J Immunol Res. 2014. PMID: 25126584 Free PMC article. Review.
Cited by
-
Cell therapy for neurological disorders.Nat Med. 2024 Oct;30(10):2756-2770. doi: 10.1038/s41591-024-03281-3. Epub 2024 Oct 15. Nat Med. 2024. PMID: 39407034 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials